Tag:
Dainippon Sumitomo
Latest Headlines
Latest Headlines
Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout
Boston Biomedical's focus on targeting cancer stem cells has paid off.
Chelsea Therapeutics reports positive efficacy results in PhII fibromyalgia study
Chelsea Therapeutics ( $CHTP ) has racked up some more positive efficacy data for its lead drug droxidopa , which is now up for review at the FDA. Investigators reported the drug spurred a statistically
Sunovion's inhaled steroid for allergies looks good in Ph3 amid FDA review
While the FDA reviews its application for approval of the experimental drug, Sunovion Pharmaceuticals revealed upbeat data from a major Phase III trial of its ciclesonide nasal aerosol against...
Intercept lands $315M Asian pact for liver disease drug
Japan's Dainippon Sumitomo is slapping down $15 million and promising up to $300 million more in milestones in exchange for the rights to Intercept Pharmaceuticals' late-stage liver disease drug in
FDA approves Dainippon's Latuda for schizophrenia
The FDA has given the green light to Dainippon Sumitomo Pharma's Latuda ( lurasidone ), an atypical antipsychotic. The drug is designed to work like other atypcals such as Zyprexa, Risperdal or
FDA declines to approve Dainippon's epilepsy drug
Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion , the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the
Sepracor merges and CEO Adams jumps to Inspire
With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.
Dainippon files for approval of blockbuster schizophrenia drug
Dainippon Sumitomo has filed for FDA approval of its prospective blockbuster schizophrenia drug lurasidone , beating its own timetable as the Japanese pharma giant stays on course toward an expected
Sepracor CEO in line for $11M golden handshake
Japan's Dainippon Sumitomo has completed its $2.6 billion deal to buy Sepracor and has set aside a tidy package of $11 million for CEO Adrian Adams ( photo ). The Boston Business Journal checked out
Sepracor investors try to derail $2.6B Dainippon buyout
Two of Sepracor's stockholders are shouting foul in a lawsuit aimed at derailing Dainippon Sumitomo's $2.6 billion acquisition pact , hoping for a richer deal in the process. Close to a week ago,
